BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Conference Call Participants Ken Cacciatore - Cowen and Company Chris Raymond - Piper Sandler Daniel Wolle - JPMorgan Joe Spak - RBC Capital Jon Wolleben - JMP Securities Gena Wa ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BCRX Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ...

Key Points Company and Industry * **Company**: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) * **Industry**: Biotechnology, Rare Diseases Core Points and Evidence * **ORLADEYO Launch**: The launch of ORLADEYO continues to be strong, with revenue on track to exceed $250 million this year. New patient starts remain consistently strong for six quarters in a row. * **Revenue Guidance**: The company has refined its guidance for this year to between $255 million and $265 million and continues to track toward $1 billion at peak. * **Pipeline**: BioCryst has an exciting pipeline of compounds for other patients suffering from rare diseases, including BCX9930 for PNH and complement-mediated renal diseases. * **Capital Allocation**: The company is disciplined in its capital allocation decisions, focusing on objective data and insights to make informed business decisions. * **BCX9930**: The FDA has lifted the partial clinical hold on the BCX9930 program, allowing pivotal trials and PNH enrollment to resume. The company is testing a lower dose of BCX9930 (400 mg BID) to mitigate potential kidney effects. * **ORLADEYO Market Share**: ORLADEYO has a growing market share, with about 12% share in the U.S. and significant potential for further growth. Other Important Points * **Patient Retention**: The company has seen an improvement in patient retention for ORLADEYO, with the fewest number of discontinuations since Q3 of last year. * **Access and Reimbursement**: The company has made progress toward the globalization of ORLADEYO, with regulatory approvals in Canada and Switzerland and final price agreements in Germany, France, and Switzerland. * **Complement Area**: The company sees the complement area and the ability to bring oral drugs to fill large unmet needs for rare disease patients as a massive opportunity. * **Data-Driven Approach**: The company emphasizes the importance of objectivity and following the evidence and data in its decision-making process. References * [7] * [8] * [9] * [10] * [11] * [12] * [13] * [14] * [15] * [16] * [17] * [18] * [19] * [20] * [21] * [22] * [23] * [24] * [25] * [26] * [27] * [28] * [29] * [30] * [31] * [32] * [33] * [34] * [35] * [36] * [37] * [38] * [39] * [40] * [41] * [42] * [43] * [44] * [45] * [46] * [47] * [48] * [49] * [50] * [51] * [52] * [53] * [54] * [55] * [56] * [57] * [58] * [59] * [60] * [61] * [62] * [63] * [64] * [65] * [66] * [67] * [68] * [69] * [70] * [71] * [72] * [73] * [74] * [75] * [76] * [77] * [78] * [79] * [80] * [81] * [82] * [83] * [84] * [85] * [86] * [87] * [88] * [89] * [90] * [91] * [92] * [93] * [94] * [95] * [96] * [97] * [98] * [99] * [100] * [101]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ______________________ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) D ...

Call Start: 08:30 January 1, 0000 9:24 AM ET BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2022 Earnings Conference Call May 5, 2022 08:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Dr. Bill Sheridan - Chief Medical Officer Charlie Gayer - Chief Commercial Officer Dr. Helen Thackray - Chief R&D Officer Conference Call Participants Ken Cacciatore - Cowen and Company Jon Wolleben - JMP Securiti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in ...